gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NRIXHealthcarePharmaceuticals

Nurix Therapeutics, Inc. Common stock (NRIX)

$15.95−38.23%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$15.95▲ 30.10% in range
Nov 4, 2025Low $12.17 · High $27.79Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nurix Therapeutics closed at $15.95 on Nov 4, down 38.23%, 42.6% below its 52-week closing high. Volume of 19.6M shares was 6.87× its 20-day average (well above normal).

Split-adjusted performance: -29.4% over one month, -5.5% over six months, +26.4% over one year.

In the quarter ended Aug 31, 2026, revenue was $673.06M, up 8426.3% from a year earlier, with a net margin of 81.7%.

Short interest was 20.6M shares at the Oct 15 settlement, up 16.7% from the prior report (21.0% of float, 9.2 days to cover).

Market cap$1.74B109.2M shares
Revenue · quarter$673.1M+8426.3% YoY
Diluted EPS$4.73—
P/E · TTM5.9×P/S 2.5×
Net margin81.7%Gross 100.0%
Dividend yieldNone
52-week range12.17 – 27.79−42.6% from high
Volume19.6M6.87× 20-day avg
Volatility · 60d104.6%Annualised
Short % of float21.0%9.2 days to cover
Net cash$1.05BCash $1.05B
Next earnings—Not scheduled
Split-adjusted performance
1W −41.5%1M −29.4%3M −36.8%6M −5.5%YTD −15.9%1Y +26.4%3Y +203.2%5Y −53.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum68
Revenue growth100
Net margin98
Value (low P/E)83
Size79

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short20.6M+16.7% vs prior
Days to cover9.2Settled Oct 15
% of float21.0%
Short vol. 10d42.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NRIXNurix Therapeutics$15.95−38.23%−5.5%+8426.3%81.7%5.9$1.74B
STOKStoke Therapeutics$27.45+1.70%−17.5%+5.9%−654.3%—$1.77BCompare
RAREUltragenyx Pharmaceutical$17.16+3.19%−33.8%+28.1%−43.0%—$1.69BCompare
PGENPrecigen$5.06−3.71%+14.9%+6322.7%36.5%—$1.81BCompare
BRVEBraveheart Bio$20.11−6.01%————$1.81BCompare
GENBGenerate Biomedicines$14.16+2.24%——−1065.2%—$1.82BCompare
NUVBNuvation Bio$4.73+0.85%−6.2%+555.6%−198.3%—$1.66BCompare
KLRAKailera Therapeutics$12.80+1.75%————$1.66BCompare
ANIPANI Pharmaceuticals$71.65−0.87%−14.8%+25.9%8.6%16.5$1.65BCompare

News about Nurix Therapeutics

All news →
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research · Oct 12, 2026NeutralNurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer MarketBenzinga · Jun 8, 2026▲ PositiveNurix Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · May 13, 2026▲ PositiveNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026GlobeNewswire Inc. · Apr 22, 2026▲ PositiveNurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire Inc. · Apr 8, 2026▲ Positive

Quick answers

What does Nurix Therapeutics do?
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities.
What is NRIX's market cap?
$1.74B, based on the Nov 4 close of $15.95.
What is NRIX's P/E ratio?
5.9× trailing-twelve-month earnings of $294.88M.
Does Nurix Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NRIX is sold short?
20.6M shares, 21.0% of float, as of Oct 15, 2026.
What sector is NRIX in?
Healthcare, in the Pharmaceuticals industry.

About Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

HQ: Brisbane, CA357 employeesListed Jul 24, 2020nurixtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology